Multiple Companies

 
News Articles for Multiple Companies top ^
2014/3/18
For MS Awareness Month, MSAA Launches Effort to Get More People with MS in the Pool CHERRY HILL, N.J. , March 18, 2014 /PRNewswire/ -- In honor of Multiple Sclerosis (MS) Awareness Month, the Multiple Sclerosis Association of America (MSAA), through a collaborative partnership with Genzyme, a Sanofi company, is proud to announce the stories from three individuals in the MS community who describe how swimming has helped manage their MS symptoms and improve their overall well-being.
Sign-up for Multiple Sclerosis Association of America's Nationwide Search Uncovers Inspiring Stories of People Living with MS Who Swim for Better Health investment picks
2013/7/18
SAN DIEGO, July 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the funding and regulatory approvals of a NIH-based grant for a Phase 2b trial of MN-166 (ibudilast) in subjects with progressive multiple sclerosis (progressive MS). The principal investigator will be Robert Fox, M.D., M.S., FAAN, Staff Neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic.
Sign-up for MediciNova Announces Initiation of a Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis investment picks
2013/9/23
Biogen Idec (NASDAQ: BIIB) will present 58 data sets from the company’s multiple sclerosis (MS) clinical portfolio of approved and investigational products at the 29 th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, October 2-5.
Sign-up for Biogen Idec to Present Extensive New Data from Its Robust Multiple Sclerosis Portfolio at ECTRIMS investment picks
Genzyme , a Sanofi company (EURONEXT: SAN and NYSE: SNY) announced today that new data from its Aubagio ® (teriflunomide) and Lemtrada™ (alemtuzumab) clinical development programs will be presented during the 29 th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18 th Annual Conference of Rehabilitation in MS (RIMS) to be held in Copenhagen, Denmark, October 2-5.
Sign-up for Genzyme’s Multiple Sclerosis Franchise Featured at ECTRIMS investment picks
2014/2/11
Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma Canada NewsWire POMALYST Is A New Option For Patients Whose Disease Has Progressed Despite Treatment With Available Therapies MISSISSAUGA, ON , Feb.
Sign-up for Health Canada Approves (Pr)POMALYST(TM) (Pomalidomide Capsules) Providing New Hope For Patients With Progressive Multiple Myeloma investment picks
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS) announced it will be a key sponsor of the National Multiple Sclerosis Society’s Walk MS series of events being held in the Houston area and Austin, Texas, during October and November.
Sign-up for Opexa Therapeutics Supports National Multiple Sclerosis Society as a Corporate Sponsor of Walk MS investment picks
Trulia (NYSE:TRLA), a leading online marketplace for home buyers, sellers, renters, real estate agents and brokers , today announced a new partnership with the North Alabama Multiple Listing Service (NALMLS) to directly syndicate home listing data to Trulia’s popular website.
Sign-up for North Alabama Multiple Listing Service to Directly Syndicate Home Listing Data on Trulia with Trulia Data Connect investment picks
Health Canada Approves Genzyme's AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Remitting Multiple Sclerosis Canada NewsWire MISSISSAUGA, ON , Nov.
Sign-up for Health Canada Approves Genzyme's AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Remitting Multiple Sclerosis investment picks
CHERRY HILL, N.J. , Dec.
Sign-up for The Multiple Sclerosis Association of America Announces Swim for MS - Why I Swim Campaign investment picks
Television host and film and TV producer, Jack Osbourne, is helping to raise awareness about multiple sclerosis (MS), through a new campaign called You Don’t Know Jack About MS ™. The online documentary series, sponsored by Teva Pharmaceuticals, chronicles Jack Osbourne and his life with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, in which a person experiences episodes of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs.
Sign-up for “Dancing with the Stars” Finalist Jack Osbourne Offers Inside Look at His Life with Multiple Sclerosis through You Don’t Know Jack About MS™ Campaign investment picks
Alkermes plc (NASDAQ:ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 14/032,736, entitled “Prodrugs of fumarates and their use in treating various diseases.” The allowed composition of matter claims will cover Alkermes’ MMF prodrug, ALKS 8700, a proprietary, small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis.
Sign-up for Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis investment picks
2014/1/27
Marathon Hits Multiple Gold Intervals in Shallow Drilling at the Victory Gold Deposit Canada NewsWire TORONTO , Jan.
Sign-up for Marathon Hits Multiple Gold Intervals in Shallow Drilling at the Victory Gold Deposit investment picks
2014/2/27
First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada Canada NewsWire MISSISSAUGA, ON , Feb.
Sign-up for First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada investment picks
-Sativex Already Undergoing Phase 3 Program in the U.S. as a Treatment for Cancer Pain- LONDON , Aug.
Sign-up for GW Pharmaceuticals plc Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis investment picks
A&W and the Multiple Sclerosis Society of Canada team up to end MS for the 5th Annual Cruisin' for a Cause Canada NewsWire $1 from every Teen Burger® sold across Canada will go towards helping those living with MS VANCOUVER , Aug.
Sign-up for A&W and the Multiple Sclerosis Society of Canada team up to end MS for the 5th Annual Cruisin' for a Cause investment picks
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® , a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce that Tcelna has been featured in a FOX Atlanta Channel 5 Newscast titled “New Therapy Could Battle Autoimmune Diseases.” The story by FOX Medical Team reporter Beth Galvin highlights Opexa’s ongoing Phase IIb clinical trial in secondary progressive MS and provides an interview with Dr.
Sign-up for Opexa Therapeutics’ Therapy for Multiple Sclerosis Featured in FOX Television News Story investment picks
2013/10/2
Acorda Therapeutics, Inc. (Nasdaq: ACOR ) will present new research at the 29 th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on AMPYRA ®  (dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis.
Sign-up for Acorda to Present New Research on AMPYRA® (dalfampridine-ER) at 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) investment picks
Accenture (NYSE:ACN) has signed an agreement with Astellas Pharma Inc. (TSE:4503, “Astellas”) to provide business process outsourcing (BPO) services for multiple business functions.
Sign-up for Astellas Signs Agreement with Accenture to Deliver Business Process Outsourcing to Multiple Business Areas investment picks
2013/11/28
RBC Global Asset Management Inc. receives multiple distinctions at Morningstar Canadian Investment Awards Canada NewsWire TORONTO , Nov.
Sign-up for RBC Global Asset Management Inc. receives multiple distinctions at Morningstar Canadian Investment Awards investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Multiple Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Multinational Companies  |  Next: Multiple Managers